Padma Kodukula
Chief Executive Officer
ScopeSys
ScopeSys provides a single‑molecule imaging platform that uses Convex Lens‑induced Confinement (CLiC) to create nanoscopic observation volumes for high‑throughput analysis. The system visualizes and quantifies interactions of RNA, DNA, and nanoparticle‑based therapeutics—such as mRNA‑lipid nanoparticle binding—delivering kinetic and binding metrics that accelerate sequence engineering and formulation optimization for pharmaceutical and biotech R&D.
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current drug development pipelines for RNA, DNA, and nanoparticle‑delivered therapeutics rely on bulk or ensemble assays that cannot resolve individual molecular interactions. This limitation hampers precise optimization of therapeutic sequences, formulation loading, and mechanistic understanding, leading to longer development cycles and higher attrition rates.
Solution
ScopeSys offers a commercial‑stage single‑molecule imaging platform built around Convex Lens‑induced Confinement (CLiC) technology. The CLiC approach creates nanoscopic observation volumes that enable high‑throughput measurements while preserving single‑molecule resolution. By directly visualizing interactions such as mRNA‑lipid nanoparticle binding and nucleic acid conformational changes, the platform provides quantitative data that guide sequence engineering and formulation optimization. The system integrates with standard laboratory workflows, allowing pharmaceutical and biotech R&D teams to iterate designs faster and with greater confidence. Resulting analytics support the development of more efficacious active pharmaceutical ingredients and delivery vehicles.
Target Audience
Primary customers are pharmaceutical and biotechnology R&D groups developing RNA, DNA, or nanoparticle‑based therapeutics, as well as academic labs focused on genomic‑medicine analytics.
Features
- Convex Lens‑induced Confinement (CLiC) creates stable nanovolumes for single‑molecule detection at throughput rates comparable to ensemble assays
- Real‑time visualization of mRNA‑lipid nanoparticle interactions with single‑particle resolution
- Quantitative analysis of nucleic acid sequence variants to inform potency and stability improvements
- Compatibility with RNA, DNA, and nanoparticle‑based therapeutic formats without extensive sample preparation
- Automated data acquisition and processing pipeline that outputs kinetic and binding metrics for downstream modeling
- Modular hardware and software design that integrates into existing microscopy or plate‑reader infrastructures
- Secure, HIPAA‑compliant data handling for confidential pharmaceutical research